MediWound (NASDAQ:MDWD) Upgraded at StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a research report report published on Wednesday morning.

Separately, HC Wainwright reaffirmed a buy rating and issued a $28.00 price objective on shares of MediWound in a report on Thursday, May 30th.

MediWound Stock Performance

MDWD stock opened at $19.60 on Wednesday. MediWound has a one year low of $7.10 and a one year high of $24.00. The stock has a market capitalization of $181.89 million, a PE ratio of -14.20 and a beta of 0.81. The company has a fifty day moving average of $16.61 and a 200-day moving average of $14.79.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $4.96 million during the quarter, compared to the consensus estimate of $4.65 million. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. Equities analysts forecast that MediWound will post -1.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MediWound

A number of large investors have recently made changes to their positions in the business. Essex Investment Management Co. LLC grew its stake in shares of MediWound by 241.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock valued at $1,888,000 after buying an additional 93,705 shares in the last quarter. Yelin Lapidot Holdings Management Ltd. boosted its position in shares of MediWound by 45.7% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after acquiring an additional 39,348 shares during the period. Sargent Investment Group LLC boosted its position in shares of MediWound by 7.0% in the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after acquiring an additional 7,125 shares during the period. Silverberg Bernstein Capital Management LLC boosted its position in shares of MediWound by 7.8% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 85,184 shares of the biopharmaceutical company’s stock valued at $1,214,000 after acquiring an additional 6,200 shares during the period. Finally, Janney Montgomery Scott LLC acquired a new position in shares of MediWound in the first quarter valued at $427,000. Institutional investors and hedge funds own 46.83% of the company’s stock.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.